Premium
Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes
Author(s) -
Vaage Jan,
Donovan Dorothy,
Mayhew Eric,
Abra Robert,
Huang Anthony
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19931215)72:12<3671::aid-cncr2820721219>3.0.co;2-u
Subject(s) - liposome , doxorubicin hydrochloride , medicine , doxorubicin , pharmacology , ovarian carcinoma , drug , chemotherapy , polyethylene glycol , cancer research , ovarian cancer , chemistry , cancer , biochemistry
Background. This study compared the therapeutic effects of doxorubicin hydrochloride in saline and in sterically stabilized, long‐circulating liposomes composed of hydrogenated soy phosphatidylcholine/cholesterol/polyethylene glycol‐distearoyl‐phosphatidyl‐ethanolamine (Doxil). Methods. The drug formulations were injected intravenously or intraperitoneally to treat the human ovarian carcinoma HEY, which was implanted subcutaneously or intraperitoneally into mature female Swiss nude mice. Results. The long‐circulating liposome formulation was significantly more effective than was the free drug in inhibiting tumor growth and in producing cure. The liposome formulation was significantly less toxic than was the free drug. This is the first demonstration of the therapeutic effectiveness of doxorubicin in sterically stabilized liposomes against human tumor xenografts. Conclusions. The encapsulation of doxorubicin in long‐circulating liposomes significantly enhanced the therapeutic efficacy of the drug against a human ovarian carcinoma.